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Abstract
Background: The experience of clinicians in charge of the in-hospital management of peritonsillar abscesses
supports the association between severe forms and anti-inflammatory drug (AID) consumption. However, this
observation is based on a limited number of clinical studies. Our objective was to assess the prevalence and impact
of AID consumption in patients with peritonsillar abscesses.
Methods: All patients referred to the ear, nose and throat surgery department for a peritonsillar abscess were
included in a retrospective cohort study (2012–2014).
Results: Among the 216 included patients (male, 55 %; median age, 32 years [IQR, 26–40]), 127 had received AID
(59 %), including corticosteroids (n = 67, 31 %) and/or non-steroidal AIDs (NSAIDs, n = 76, 35 %). 199 patients (92 %)
benefit from a puncture and 5 (2 %) from a surgery under general anesthesia, associated with ceftriaxone/
metronidazole (51 %) or amoxicillin/clavulanic acid (46 %). An iterative surgical procedure was required in 93 cases
(43 %), including 19 % under general anesthesia. Bacteriological analysis (79 %) mainly disclosed streptococci (66 %)
of A (18 %) and/or milleri (33 %) groups. The prevalence of anaerobes was higher in patients using AIDs (46 %
versus 29 %, p = 0.034), regardless of prior antibiotic therapy. 65 patients benefited from a CT-scan; AID
consumption was associated with larger abscesses (6.8 [IQR, 3.7–12.7] versus 2.9 [IQR, 0.9–7.8] cm3; p = 0.005). AID
consumption was not a risk factor of iterative surgical procedure.
Conclusions: In comparison to the prescribing habits in uncomplicated upper respiratory tract infection, the high
prevalence of AID consumption in patients with peritonsillar suppuration suggests a role of AIDs in promoting
these complications.
Keywords: Pharyngeal infection, Tonsillar abscess, Anti-inflammatory drugs, Nonsteroidal anti-inflammatory
drugs, Corticosteroids
Background
Despite healthcare authorities’ warnings in the current
guidelines about the use of corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs) in patients
with upper respiratory tract infection, including pha-
ryngitis, they are still widely/regularly used [1–4]. The
experience of many physicians in charge of the in-hospital
management of peritonsillar abscesses supports the asso-
ciation between anti-inflammatory drug (AID) con-
sumption and such severe forms of infection. If the
negative impact of long-term corticosteroid therapy
has been well demonstrated in various clinical situa-
tions such as pyogenic infections, tuberculosis, severe
forms of varicella, viral hepatitis B and C or invasive
fungal infections [5–12], no study has linked the use
of AIDs, including NSAIDs, with the occurrence of
peritonsillar abscesses. In this setting, we aimed to
evaluate the prevalence of AID consumption among
patients with peritonsillar abscesses, and to evaluate
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All patients referred to the ear, nose and throat (ENT)
surgery department of our institution for peri-tonsillar
abscess(es) between 1st January 2012 and 31st December
2014 were included in a retrospective single-center ob-
servational cohort. Patients were selected from a hospital
information system determined by the International
Classification of Diseases (ICD-10), 10th revision, using
the codes corresponding to peritonsillar abscess (J36),
pharyngeal abscess (J39.0 and J39.1), cellulitis and ab-
scess of the mouth (K12.2), cellulitis of the face (L03.2),
cellulitis of other sites (L03.8) or unspecified cellulitis
(L03.9) [13]. All medical records were reviewed to con-
firm that the final diagnosis corresponded to a periton-
sillar abscess. Doubtful cases were validated or excluded
independently by two of the study authors. In particular,
patients with cervical suppurations with no clinical and
radiological argument for a primitive tonsillar involve-
ment have been excluded.
Data collection
A standardized case report form was used to retrospect-
ively collect demographic data (gender, age), major comor-
bidities (obesity, diabetes, immunosuppression, history of
tonsil disease, and toxic habits), treatment received prior
to hospital admission (antibiotics, NSAIDs and corticoste-
roids), biological inflammatory parameters at admission
(C-reactive protein (CRP), white blood cell and neu-
trophil counts), results of microbiological analysis,
surgical (puncture/surgery under general anesthesia
(GA)) and medical management. When a CT-scan was
performed, images were reviewed for abscesses’ vol-
ume measurement by a radiologist using the formula
for approximation of the ellipsoid: 4/3 × π x ABC
where A represents the largest diameter in the hori-
zontal plan, and B and C the largest diameters in the
two others orthogonal plans. All data were collected
from the electronic medical records of the ENT and
emergency departments and from the institutional
software for biological results (CristalNet®).
Statistical analysis
The usual methods of descriptive statistics were used to
summarize the variables of the study, described by their
size (n, %) for categorical variables and their median
(interquartile range [IQR]) for continuous variables. The
number of missing data was removed from the denom-
inator for each percentage calculation. Non-parametric
tests (Chi-2, Fisher exact test, Mann–Whitney U-test)
were used to compare the study group, as appropriate.
All analysis were performed using SPSS software
(version 16.0; SPSS, Chicago, Illinois, USA).
Results
Included population
Two hundred and forty patients were admitted to the
ENT surgery department of our institution for a sup-
puration of tonsil origin between January 1st 2012 and
December 31st 2014. After exclusion of 24 patients for
whom information regarding AID consumption was not
available (10.0 %), 216 patients were finally enrolled in
the study, including 119 men (55.1 %) with a median age
of 32.5 years (IQR, 25.7–39.5). Main demographic char-
acteristics and comorbidities of patients are summarized
in Table 1.
Pre-hospital treatment
One hundred and twenty-seven patients (58.4 %) had
received AIDs prior to hospital admission, including 76
patients (59.8 %) receiving NSAIDs for a median
duration of 3 days (IQR, 2.0–5.0) and 67 patients
(52.8 %) treated by oral corticosteroids for 4 days (IQR,
2.0–6.0). Of note, 16 patients (7.4 %) received both
NSAIDs and oral corticosteroids.
One hundred and thirty-six patients (63 %) had re-
ceived antibiotics prior to hospital care. The main antibi-
otics prescribed before admission were amoxicillin and
clavulanic acid (n = 56, 41.2 %), amoxicillin (n = 43,
31.6 %), macrolide (n = 17, 12.5 %), resulting in an effect-
ive anti-anaerobic therapy in 60 cases (44.1 %).
In-hospital management
All but one patient (99.5 %) were hospitalized for a
median of 3 days (IQR, 3.0–4.0), 3 of whom required
intensive care unit (ICU) admission. Upon admission, 77
patients (35.6 %) benefited from a CT scan, mainly in
case of doubtful diagnosis. Images were available in 65
patients (30.1 %), of 6 (9.2 %) had bilateral abscesses
(Fig. 1). The initial biological findings showed an inflam-
matory syndrome in all patients (i.e. CRP > 10 mg/L),
with a median CRP level at 90.0 mg/L (IQR, 44.4–
156.5). Two hundred and three patients (94 %) required
an abscess drainage puncture upon admission, with or
without incision under local anesthesia (LA) (n = 199,
92.1 %) or a surgical drainage/excision under general
anesthesia (GA) (n = 5, 2.3 %). The incision under LA
was deemed insufficient for one patient, requiring im-
mediate surgical procedure under GA. Of note, the
diagnosis of peritonsillar abscess was confirmed by
CT-scan in 9 of the 13 patients who did not benefit
from drainage. In the four others, the diagnosis was
clinically based, even if the abscess did not appear
voluminous enough to benefit from a puncture. Itera-
tive surgical procedure was required in 93 patients
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(43.1 %), including 91 (97.8 %) transoral puncture/
drainage (including 16 under GA) and two cervico-
tomies for local extension of the infection.
Two hundred and fourteen patients received intra-
venous antibiotics (99.1 %) for at least one day. The
main antimicrobials were amoxicillin-clavulanic acid
(n = 98, 45.4 %) or ceftriaxone-metronidazole combin-
ation (n = 110, 51 %), except in rare cases of allergy.
The total duration of antibiotic therapy was 12.5 days
(IQR, 11.0–15.0), including 10.0 days (IQR, 10.0–11.0)
from hospital admission.
No descending mediastinitis was observed. No related-
fatality case was recorded.
Bacteriological findings
Microbiological analysis were performed in 169 (78.2 %)
patients, yielding a plurimicrobial infection in 36.1 % of
cases (n = 61). The most frequently involved bacteria
were streptococci of milleri group (32.7 %) followed by
Fusobacterium spp. (25.6 %; predominantly including F.
necrophorum [n = 30, 90.7 %]) and group A Streptococcus
(17.9 %). All of the bacteriological results are presented
in Table 2.
Impact of anti-inflammatory drugs
The demographic characteristics of patients receiving
or not AID prior to admission were similar (Table 1).
Table 1 Demographics and comorbidities of the 216 included patients, and comparison according to the consumption of
anti-inflammatory drugs prior to admission
Total population No AID consumption AID consumption p-value
Demographics 216 89 (41.2 %) 127 (58.7 %)
Sex (male) 119 (55.1 %) 52 (58.4 %) 67 (52.8 %) 0.410
Age (years) 32.2 (25.7–39.5) 31.3 (25.6–38.9) 32.8 (25.7–39.7) 0.670
Comorbidities
BMI (kg/cm2) 23.6 (21.7–26.5) 25.1 (22.0–28.6) 23.4 (20.6–25.8) 0.091
Diabetes 3 (1.4 %) 3 (3.4 %) 0 (0.0 %) 0.069
Chronic respiratory disease 2 (0.9 %) 1 (1.1 %) 1 (0.8 %) 1.000
Pharyngitis 24 (11.1 %) 13 (14.6 %) 11 (8.7 %) 0.171
Peritonsillar suppuration 16 (7.4 %) 9 (10.1 %) 7 (5.5 %) 0.204
Immunosuppression 5 (2.3 %) 1 (1.1 %) 4 (3.1 %) 0.651
Hematological malignancy or solid tumor 2 (0.9 %) 0 (0 %) 2 (1.6 %) 0.513
Tabaco consumption 63 (52.1 %) 30 (53.6 %) 33 (50.8 %) 0.758
Data are presented as n (%) for dichotomic variables and median (IQR) for continuous variables. For the calculation of each percentage, the number of missing
values was excluded from the denominator. The two groups were compared by non-parametric tests (chi-square test, Fisher exact test and Mann–Whitney U-test),
as appropriate
AID anti-inflammatory drug, BMI body mass index
Fig. 1 Horizontal (panel a) and coronal (panel b) CT-scan disclosing voluminous bilateral tonsillar abscesses (asterisks) in one of the patient included in
the study who had consumed AID before hospital admission
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Pre-hospital antibiotic use was more frequent in pa-
tients receiving AID (70.1 % versus 52.8 %; p = 0.010).
AID consumption did not impact hospital length of
stay (median of 3.0 days for both groups; p = 0.17)
nor ICU admission (2 in the AID group and 1 in the
group without AID). Baseline CRP level was signifi-
cantly higher in the group without AID (109.5 mg/L
[IQR, 66.9–172.5] versus 72.4 mg/L [IQR, 38.3–133];
p = 0.002). Conversely, white blood cell count was
higher in patients treated with AID (15,400 cells/mm3
[IQR, 12,500–18,300] versus 13,500 cells/mm3 [IQR,
12,000–16,200]; p = 0.031). Concerning radiological
results, 6 patients had bilateral abscesses, including 4
(11.4 %) in the AID group and 2 (6.7 %) in patients
without AID (p = 0.678). AID consumption was asso-
ciated with significantly larger abscesses (6.8 [IQR,
3.7–12.7] versus 2.9 [IQR, 0.9–7.8] cm3; p = 0.005).
Regarding bacteriological findings, the prevalence of
anaerobic bacteria was higher in patients who re-
ceived AIDs (45.6 % versus 29.2 %; p = 0.034), through
an overrepresentation of Fusobacterium (31.1 % ver-
sus 16.9 %; p = 0.041). Given these results, additional
analysis comparing patients infected or not by anaer-
obes showed no significant difference regarding the
nature of antimicrobial use before sampling (Table 3).
Regarding in-hospital management, there was no
difference between the needs for surgery under GA and/
or iterative drainages between the two groups (Table 4).
However, the puncture was more frequently successful
in draining pus in patients treated by AIDs (75.6 %
versus 62.9 %; p = 0.045). Of note, two patients required
cervicotomy, all in the AID group (1.6 %). AID
consumption impacted neither the nature nor the
duration of antibiotic use.
Finally, no differences were found between patients
receiving NSAIDs or corticosteroids.
Table 2 Bacteriological findings in 169 of the 216 patients included, and comparison according to the consumption of
anti-inflammatory drugs prior to admission
Total
population








p-value p-value p-value p-value
Bacteriological analysis 169 (78.2 %) 65 (73.0 %) 104 (81.9 %) 0.125 65 (85.5 %) 0.268 55 (82.1 %) 0.588 0.632
Streptococcus spp 110 (65.5 %) 44 (67.7 %) 66 (64.1 %) 0.631 40 (62.5 %) 0.424 37 (67.3 %) 0.914 0.548
S. pyogenes 30 (17.9 %) 17 (26.2 %) 13 (12.6 %) 0.026 10 (15.6 %) 0.512 3 (5.5 %) 0.022 0.131
S. milleri group 55 (32.7 %) 19 (29.2 %) 36 (35.0 %) 0.442 19 (29.7 %) 0.452 25 (45.5 %) 0.136 0.040
Staphylococcus
aureus
6 (3.6 %) 4 (6.2 %) 2 (1.9 %) 0.207 1 (1.6 %) 0.393 1 (1.8 %) 0.648 1.000
Haemophilus spp 4 (2.4 %) 2 (3.1 %) 2 (1.9 %) 0.641 1 (1.6 %) 1.000 1 (1.8 %) 1.000 1.000
Anaerobes 66 (39.3 %) 19 (29.2 %) 47 (45.6 %) 0.034 26 (40.6 %) 0.070 25 (45.5 %) 0.012 0.457
Fusobacterium spp 43 (25.6 %) 11 (16.9 %) 32 (31.1 %) 0.041 18 (28.1 %) 0.043 16 (29.1 %) 0.028 0.802
Prevotella spp 11 (6.5 %) 2 (3.1 %) 9 (8.7 %) 0.206 6 (9.4 %) 0.110 4 (7.3 %) 0.361 0.726
Plurimicrobial
infection
61 (36.1 %) 20 (30.8 %) 41 (32.5 %) 0.254 24 (36.9 %) 0.658 24 (43.6 %) 0.186 0.395
Data are presented as n (%). For the calculation of each percentage, the number of missing values was excluded from the denominator. Groups were compared
by non-parametric tests (chi-square and Fisher exact tests), as appropriate
AID anti-inflammatory drug, NSAID non-steroidal anti-inflammatory drug, vs. versus
aExcluding patients receiving both NSAIDs and corticosteroids
Table 3 Comparison of pre-hospital antibimicrobial use in patients infected or not by anaerobic bacteria
Anaerobes No anaerobes p-value
n 66 102
Pre-hospital antibiotic therapy 42 (63.6 %) 64 (62.7 %) 0.907
Amoxicillin 10 (15.2 %) 23 (22.5 %) 0.239
Amoxicillin - clavulanic acid 15 (22.7 %) 28 (27.5 %) 0.493
Clindamycin 2 (3.0 %) 0 (0.0 %) 0.153
Anti-anaerobes therapy 17 (28.5 %) 29 (28.4 %) 0.704
Antimicrobial therapy duration (days) 4.0 (3.0–7.0) 3.0 (2.0–5.0) 0.265
Data are presented as n (%) for dichotomic variables and median (IQR) for continuous variables. For the calculation of each percentage, the number of missing
values was excluded from the denominator. The two groups were compared by non-parametric tests (chi-square test, Fisher exact test and Mann–Whitney U-test),
as appropriate
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Table 4 In-hospital management of the 216 included patients, and comparison according to the consumption of anti-inflammatory drugs prior to admission








p-value p-value p-value p-value
n 216 89 (41.2 %) 127 (58.7 %) 76 (35.2 %) 67 (31.0 %)
Paraclinical tests
CT-scan 77 (35.6 %) 38 (42.7 %) 39 (30.7 %) 0.070 23 (30.3 %) 0.305 19 (28.4 %) 0.185 0.842
Abscess volume
(cm3)
4.4 (1.6–10.2) 2.9 (0.9–7.8) 6.8 (3.7–12.7) 0.005 5.7 (3.2–10.6) 0.028 7.1 (1.9–13.5) 0.049 0.728
CRP (mg/L) 90.0 (44.4–156.5) 109.5 (66.9–172.8) 72.4 (38.3–133.0) 0.002 95.1 (50.9–181.0) 0.663 47.5 (26.5–81.5) <10−3 <10−3
WBC (/mm3) 14,400 (12,100–17,700) 13,500 (12,000–16,200) 15,400 (12,50–18,300) 0.031 15,600 (12,600–17,700) 0.131 15,500 (12,500–19,100) 0.111 0.605
Neutrophils (/mm3) 13,600 (10,100–16,200) 12,800 (9400–15,600) 14,100 (10,400–16,500) 0.326 14,200 (11,300–15,600) 0.437 14,100 (10,300–17,000) 0.454 0.927
Hospitalisation 215 (99.5 %) 88 (98.9 %) 127 (100.0 %) 0.412 76 (100.0 %) 1.000 67 (100.0 %) 1.000 NC
Hospital stay (d) 3.0 (3.0–4.0) 3.0 (3.0–4.0) 3.0 (3.0–4.0) 0.170 3.0 (3.0–4.0) 0.492 3.0 (3.0–4.0) 0.066 0.344
ICU 3 (1.4 %) 1 (1.1 %) 2 (1.6 %) 1.000 2 (2.6 %) 0.565 0 (0.0 %) 1.000 0.499
Surgical management 203 (94 %) 83 (93.3 %) 120 (94.5 %) 0.708 73 (96.1 %) 0.740 63 (94 %) 1.000 0.539
Puncture/Incision 199 (92.1 %) 82 (92.1 %) 117 (92.1 %) 0.998 71 (93.4 %) 0.918 62 (92.5 %) 0.693 0.787
Productive puncture 152 (70.4 %) 56 (62.9 %) 96 (75.6 %) 0.045 58 (76.3 %) 0.268 53 (79.1 %) 0.160 0.831
Initial 199 (92.1 %) 82 (92.1 %) 117 (92.1 %) 0.998 71 (93.4 %) 0.918 62 (92.5 %) 0.758 0.787
Secondary 80 (37 %) 34 (38.2 %) 46 (36.2 %) 0.767 31 (40.8 %) 0.849 24 (35.8) 0.294 0.419
Surgery under GA 21 (9.7 %) 9 (10.1 %) 12 (9.4 %) 0.871 10 (13.2 %) 0.982 6 (9.0 %) 0.328 0.217
Initial 5 (2.3 %) 1 (1.1 %) 4 (3.1 %) 0.330 3 (3.9 %) 0.346 2 (3.0 %) 1.000 1.000
Secondary 18 (8.3 %) 8 (9.0 %) 10 (7.9 %) 0.806 9 (11.8 %) 0.836 4 (6.0 %) 0.155 0.122
Cervicotomy 2 (0.9 %) 0 (0.0 %) 2 (1.6 %) 0.513 2 (2.6 %) 0.161 0 (0.0 %) NC 0.499
Tonsillectomy 12 (5.6 %) 4 (4.5 %) 8 (6.3 %) 0.765 7 (9.2 %) 0.715 4 (6.0 %) 0.653 0.372
Iterative procedure 93 (43.1 %) 39 (43.8 %) 54 (42.5 %) 0.849 38 (50.0 %) 0.887 27 (40.3 %) 0.147 0.142
Medical management
IV antimicrobial therapy
214 (99.1 %) 88 (98.9 %) 126 (99.2 %) 1.000 75 (98.7 %) 0.410 66 (98.5 %) 1.000 NC
Total duration (d) 12.5 (11.0–15.0) 12.0 (11.0–15.0) 13.0 (10.0–16.0) 0.249 12.0 (10.0–15.3) 0.203 14.0 (12.0–17.5) 0.046 0.007
From hospital
admission (d)
10.0 (10.0–11.0) 10.0 (10.0–12.0) 10.0 (10.0–11.0) 0.021 10.0 (10.0–11.0) 0.204 10.0 (10.0–11.0) 0.008 0.176
Data are presented as n (%) for dichotomic variables and median (IQR) for continuous variables. For the calculation of each percentage, the number of missing values was excluded from the denominator. The two
groups were compared by non-parametric tests (chi-square test, Fisher exact test and Mann–Whitney U-test), as appropriate
AID anti-inflammatory drug, CRP C-reactive protein, CT-scan, computed tomography scan, d days, GA general anesthesia, ICU Intensive care unit, IV intravenous, NSAID non-steroidal anti-inflammatory drug, WBC white
blood cell














This study reports the largest series documenting the
impact of AIDs in patients with peritonsillar ab-
scesses. Despite limitations related to its retrospective
and observational nature, the proportion of patients
excluded because of missing data regarding the pri-
mary outcome (AID consumption) was low (10 %),
thanks to the precision of the medical records, thus
limiting a possible selection bias.
The first important result is the high frequency of
AIDs pre-hospital use in patients admitted in an ENT
surgery department for peritonsillar suppuration, com-
pared to the known prescription habits in tonsillitis
and upper respiratory infections. According to a 2013
French survey, 46 % of general practitioners (GPs) are
prescribers of NSAIDs in upper respiratory tract in-
fections [3]. In another study investigating GP and
pediatrician prescription in 701 adults and 758 chil-
dren treated for upper respiratory tract infection,
NSAIDs and/or oral corticosteroids were prescribed in
9 to 23 % of all cases, and in 15 to 22 % of tonsillitis
[4]. The few available data regarding self-medication
in this setting reveals an AID consumption rate of
14 % in sore throat [14]. In comparison, the pre-
valence approaching 60 % of AIDs consumption in
patients presenting a complicated infection suggests a
role of corticosteroids and NSAIDs in the genesis and
evolution of peritonsillar suppuration. However, a com-
parative study of patients with upper respiratory tract
infection consuming or not AIDs is required to defini-
tively draw this conclusion.
The AID impact on the inflammation process has been
well described, resulting in the inhibition of phagocytosis
[15, 16]. Corticosteroids inhibit the production and
secretion of proinflammatory cytokines by all immune
cells, and increase the number of neutrophils by redu-
cing their adhesion to the vascular endothelium, thus
preventing their diapedesis to the infection site [17].
NSAIDs impede prostaglandin production by blocking
the action of cyclooxygenase [18]. In addition to their
intended analgesic effect, NSAIDs inhibit all stages of
the innate and acquired immune responses by i) hinder-
ing several membrane enzymes of neutrophils, macro-
phages and platelets, thus preventing their migration
and chemotaxis [19]; ii) stabilizing lysosomal mem-
branes, therefore limiting degranulation [20]; iii) inhi-
biting antibody production in human B-cells [21]; and iv)
suppressing the proliferation of CD4+ and CD8+ T-cells
[22]. The high white blood cell count and low CRP
level observed in the AID group of patients of our
study are the resultant of all these mechanisms, and
suggest that the doses of AID consumed by the in-
cluded patients, even for a short period, had an effect
on the inflammatory processes.
The clinical consequences of the immunosuppression
state induced by long-term corticosteroid therapies have
been highlighted in various clinical situations [5–12].
The role of NSAIDs in the development and/or worsen-
ing of infections is less clear, but strongly suspected. For
example, NSAIDs increase the risk of skin and soft
tissue bacterial infection when used during chickenpox
[23, 24]. Their involvement in the pathogenesis of severe
fasciitis and cellulitis has also been suggested by several
studies [25–29]. They have been suspected to increase
the frequency of pleural effusions, to lengthen the dur-
ation of oxygen therapy and to major ICU admission in
patients hospitalized for community-acquired pneumo-
nia [30]. Finally, NSAIDs increase the risk of complica-
tions in acute pyelonephritis [31]. However, no similar
studies exist in upper respiratory tract infections, despite
the use of AID is suspected of being partly responsible
for the recent increased incidence of peritonsillar ab-
scesses [32]. Indeed, Demeslay et al. showed that 60 % of
163 patients suffering from peritonsillar abscess or cer-
vical cellulitis had taken AIDs [33]. In another study by
Lepelletier et al., a relation between the occurrence of a
peritonsillar abscess and self-medication with AIDs has
also been suggested, finding a 65 % exposure to AIDs
before the onset of this complicated infection [14].
Finally, Thiebaut et al. observed a high rate of AID
cunsumption in patients with cervical cellulitis with or
without descending mediastinitis [34].
In our study, patients using or not AIDs had similar
demographics and comorbidities, particularly with respect
to known risk factors for peritonsillar cellulitis as male
gender, tobacco use, tonsillitis history and immuno-
compromised status. No difference regarding in-hospital
surgical or medical management was observed. However,
abscesses were more than two and a half larger in patients
consuming AID, and the two patients requiring cervicot-
omy had received NSAIDs. If the correlation between pre-
hospital AID and antibiotic uses cannot rule out the exist-
ence of a more severe disease on first presentation in
patients receiving AID, it seems more likely that GPs
were reluctant to prescribe AID without antibiotics in
a septic context.
Finally, bacteriological findings were consistent with
the literature data, dominated by oral flora streptococci
of milleri group, Fusobacterium and Streptococcus pyo-
genes [35]. An interesting feature was the observation of
a higher proportion of anaerobes in the AID group,
unrelated with the antibiotic therapy received before
sampling. No similar finding has been reported to date.
No explanation can be advanced with certainty, but
these results suggest an influence of AIDs on the
immune system facilitating anaerobe infections. The
impact of AIDs on the pharyngeal microbiota may also
be evaluated. Another explanation may lies in a possible
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AID-related high inoculum effect, facilitating the de-
tection of fastidious organisms such as anaerobes, as
supported by the more frequently successful puncture
and the larger abscess size observed on CT-scan in
patient receiving AIDs.
Conclusions
In conclusion, the high prevalence (approaching 60 %)
of AID consumption among patients with peritonsillar
abscess suggests a role of these drugs in the deve-
lopment of severe complications of common infections.
Associated with their only symptomatic benefit, this
observation encourages interest in renewing a cautious
attitude about their systematic use in infectious diseases.
However, larger prospective studies are required to def-
initely establish whether AID consumption constitute a
trigger for severe complication during upper respiratory
tract infection. Moreover, AID consumption was associ-
ated with significantly larger abscesses, and with a higher
prevalence of anaerobes, justifying the combination of
ceftriaxone and metronidazole as first-line treatment.
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